Publication: An update on the exploratory use of curcumin in neuropsychiatric disorders
dc.affiliation.dpto | UC3M. Departamento de Bioingeniería | es |
dc.affiliation.grupoinv | UC3M. Grupo de Investigación: Biomedical Imaging and Instrumentation Group | es |
dc.contributor.author | Lamanna Rama, Nicolás | |
dc.contributor.author | Romero Miguel, Luis Diego | |
dc.contributor.author | Desco Menéndez, Manuel | |
dc.contributor.author | Soto Montenegro, Mª Luisa | |
dc.contributor.funder | Comunidad de Madrid | es |
dc.contributor.funder | Ministerio de Ciencia, Innovación y Universidades (España) | es |
dc.date.accessioned | 2023-01-25T08:29:39Z | |
dc.date.available | 2023-01-25T08:29:39Z | |
dc.date.issued | 2022-02 | |
dc.description | This article belongs to the Special Issue Dietary Antioxidants against Neurodegenerative Diseases. | en |
dc.description.abstract | Curcumin is a polyphenol extracted from the rhizome of the turmeric plant. Beyond its common use as a culinary spice in Eastern Asia, curcumin has been proposed as a therapeutic compound due to its antioxidant, anti-inflammatory and neuroprotective properties. Thus, its efficacy has been evaluated in various inflammatory-based psychiatric disorders, such as schizophrenia, depression, or autism. Our aim is to review those preclinical and clinical studies carried out in psychiatric disorders whose therapeutic approach has involved the use of curcumin and, therefore, to discern the possible positive effect of curcumin in these disorders. Preclinical studies and completed clinical trials of curcumin for psychiatric disorders published from January 2005 to October 2021 were identified through searching relevant databases until 31st October 2021. Sixty-five preclinical studies and 15 clinical trials and open-label studies were selected. Results showed a bias toward studies in depression and, to a lesser extent, schizophrenia. In all disorders, the results were positive in reducing psychiatric deficits. Despite the considerable number of beneficial outcomes reported, the small number of trials and the heterogeneity of protocols make it difficult to draw solid conclusions about the real potency of curcumin in psychiatric disorders. | en |
dc.description.sponsorship | M.L.S.-M. was supported by the Ministerio de Ciencia, Innovación y Universidades, Instituto de Salud Carlos III (project number PI17/01766, and grant number BA21/00030), co-financed by the European Regional Development Fund (ERDF), "A way to make Europe", CIBER de Salud Mental (project number CB07/09/0031), Delegación del Gobierno para el Plan Nacional sobre Drogas (project number 2017/085); and Fundación Alicia Koplowitz (FAK16/01). D.R.-M. was supported by Consejería de Educación e investigación, Comunidad de Madrid, co-funded by the European Social Fund "Investing in your future" (grant, PEJD-2018-PRE/BMD-7899). N.L.-R. was supported by the Instituto de investigación Sanitaria Gregorio Marañón, "Programa Intramural de Impulso a la I+D+I 2019". The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505). | en |
dc.format.extent | 27 | |
dc.identifier.bibliographicCitation | Lamanna-Rama, N., Romero-Miguel, D., Desco, M. & Soto-Montenegro, M. L. (2022). An update on the exploratory use of curcumin in neuropsychiatric disorders. Antioxidants, 11(2), 353. | en |
dc.identifier.doi | https://doi.org/10.3390/antiox11020353 | |
dc.identifier.issn | 2076-3921 | |
dc.identifier.publicationfirstpage | 1 | |
dc.identifier.publicationissue | 2, 353 | |
dc.identifier.publicationlastpage | 27 | |
dc.identifier.publicationtitle | Antioxidants | en |
dc.identifier.publicationvolume | 11 | |
dc.identifier.uri | https://hdl.handle.net/10016/36356 | |
dc.identifier.uxxi | AR/0000031162 | |
dc.language.iso | eng | en |
dc.publisher | MDPI | |
dc.relation.projectID | Gobierno de España. PI17/01766 | es |
dc.relation.projectID | Gobierno de España. BA21/00030 | es |
dc.relation.projectID | Comunidad de Madrid. PEJD-2018-PRE/BMD-7899 | es |
dc.relation.projectID | Gobierno de España. SEV-2015-0505 | es |
dc.rights | © 2022 by the authors. | en |
dc.rights | Atribución 3.0 España | * |
dc.rights.accessRights | open access | en |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.subject.eciencia | Biología y Biomedicina | es |
dc.subject.other | Autism | en |
dc.subject.other | Curcumin | en |
dc.subject.other | Depression | en |
dc.subject.other | Inflammation | en |
dc.subject.other | Obsessive compulsive disorder | en |
dc.subject.other | Oxidative stress | en |
dc.subject.other | Psychiatric disorders | en |
dc.subject.other | Schizophrenia | en |
dc.title | An update on the exploratory use of curcumin in neuropsychiatric disorders | en |
dc.type | research article | * |
dc.type.hasVersion | VoR | * |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1